Centessa Pharmaceuticals plc (NASDAQ:CNTA) Sees Large Growth in Short Interest

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) saw a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 4,150,000 shares, a growth of 36.1% from the January 31st total of 3,050,000 shares. Approximately 5.2% of the company's shares are short sold. Based on an average daily volume of 723,400 shares, the short-interest ratio is presently 5.7 days.

Centessa Pharmaceuticals Stock Down 3.2 %

Shares of NASDAQ CNTA traded down $0.53 during midday trading on Friday, reaching $16.23. 1,090,724 shares of the company's stock traded hands, compared to its average volume of 827,071. The company has a market cap of $2.14 billion, a price-to-earnings ratio of -10.61 and a beta of 1.54. The stock's 50 day simple moving average is $16.49 and its 200-day simple moving average is $16.10. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals has a one year low of $7.75 and a one year high of $19.09.

Insider Activity at Centessa Pharmaceuticals

In other news, insider Karen M. Anderson sold 5,876 shares of the company's stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $17.01, for a total transaction of $99,950.76. Following the transaction, the insider now owns 71,525 shares of the company's stock, valued at approximately $1,216,640.25. This represents a 7.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total value of $91,740.00. Following the sale, the general counsel now directly owns 118,265 shares of the company's stock, valued at $1,808,271.85. This represents a 4.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 359,186 shares of company stock worth $6,017,106. Insiders own 11.59% of the company's stock.

Remove Ads

Institutional Trading of Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD lifted its stake in shares of Centessa Pharmaceuticals by 14.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company's stock worth $89,854,000 after purchasing an additional 685,371 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in Centessa Pharmaceuticals by 22.0% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company's stock worth $85,744,000 after purchasing an additional 924,027 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Centessa Pharmaceuticals by 279.2% during the fourth quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company's stock valued at $82,218,000 after buying an additional 3,614,623 shares during the last quarter. Farallon Capital Management LLC boosted its holdings in shares of Centessa Pharmaceuticals by 24.3% in the 4th quarter. Farallon Capital Management LLC now owns 3,498,709 shares of the company's stock valued at $58,603,000 after buying an additional 684,391 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its position in shares of Centessa Pharmaceuticals by 26.2% in the 4th quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company's stock worth $57,396,000 after buying an additional 710,936 shares during the last quarter. Institutional investors own 82.01% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have commented on CNTA shares. Guggenheim restated a "buy" rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. Morgan Stanley reissued an "overweight" rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday. Finally, TD Cowen started coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Centessa Pharmaceuticals has an average rating of "Buy" and an average price target of $26.00.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.